| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9597288 | BDSI | Transmucosal delivery devices with enhanced uptake |
Jul, 2027
(3 years from now) | |
Onsolis is owned by Bdsi.
Onsolis contains Fentanyl Citrate.
Onsolis has a total of 1 drug patent out of which 0 drug patents have expired.
Onsolis was authorised for market use on 16 July, 2009.
Onsolis is available in film;buccal dosage forms.
Onsolis can be used as management of breakthrough pain in patients with cancer.
The generics of Onsolis are possible to be released after 23 July, 2027.
Drugs and Companies using FENTANYL CITRATE ingredient
Market Authorisation Date: 16 July, 2009
Treatment: Management of breakthrough pain in patients with cancer
Dosage: FILM;BUCCAL
ONSOLIS family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic